Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J G Ibrahim

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801J M Kirkwood, J G Ibrahim, J A Sosman, et al.
British Journal of Cancer|November 20, 2008
Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosisP Qu, H Chu, J G Ibrahim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J M Kirkwood, J G Ibrahim, V K Sondak, et al.
Public Health Genomics|January 25, 2014
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancerN T Brewer, J T Defrank, W K Chiu, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801J M Kirkwood, J G Ibrahim, J A Sosman, et al.
British Journal of Cancer|November 20, 2008
Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosisP Qu, H Chu, J G Ibrahim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J M Kirkwood, J G Ibrahim, V K Sondak, et al.
Public Health Genomics|January 25, 2014
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancerN T Brewer, J T Defrank, W K Chiu, et al.
Pageof 4